another Stanford MS story by the same author, the same week. Bit more upbeat, I'd say. wonder why?
link to WSJ
I sent the WSJ reporter an email whining about his CCSVI article. He did a great job on this newer MS article. Here's my latest email to him:
"Most MS patients are of the "relapsing-remitting" type, where the disease flares up periodically and largely disappears for long periods of time. Beta-interferon, an injectable medicine that costs about $25,000 and up annually, lowers the relapse rate by roughly one-third in the half of patients who respond."
"The drug also causes flu-like symptoms like aches, fever and muscle pain that can last for hours. The side effects often discourage patients from taking the medicine as prescribed, especially since it can take two years or more before it becomes apparent if it is helping."
Excellent coverage on the cost and relative ineffectiveness of one of the popular MS drugs.
Gutsy article for a business publication. Great job!